Company news
Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A (SSE:688266) news
Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases on 6ix. Latest, Jun 3, 2025: Announcement on Voluntary Disclosure of Clinical Data and Latest…
Press releases — page 2
Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG006 and ZG005 Released at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 2, 2025
Announcement on the Approval of Gecacitinib Hydrochloride Tablets for Marketing
May 29, 2025
Announcement on Using Some Temporarily Idle Raised Funds for Cash Management
May 16, 2025
Announcement on Voluntary Disclosure of Acceptance of New Drug Marketing Application for Treatment of Severe Alopecia Areata with Gecacitinib Hydrochloride Tablets
May 13, 2025
Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
April 24, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor
April 20, 2025
Announcement on Subproject Change, Amount Adjustment, and New Subprojects of Some Investment Projects Financed by Raised Funds
April 18, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Chemotherapy Regimen
April 9, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 26, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Platinum-based Chemotherapy Regimen
February 17, 2025
Indicative Announcement on the Renewal of Concerted Action Agreement and Changes in Equity by Actual Controllers
January 23, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials of Combination of Injectable ZG005 with Gecacitinib Hydrochloride Tablets
December 25, 2024
Announcement on Voluntary Disclosure of Inclusion of Recombinant Human Thrombin into the Catalogue Of Drugs For Basic National Medical Insurance in 2024
November 28, 2024
Announcement on Convening the Q3 2024 Performance Briefing
November 22, 2024
Announcement on Cancelling Some Special Accounts for Raised Funds
October 28, 2024
Announcement on Postponement of Some Investment Projects Financed by Raised Funds
October 25, 2024
Announcement on Voluntary Disclosure of Clinical Study Progress of ZG005 for Injection
September 25, 2024
Announcement on Voluntary Disclosure of Clinical Study Progress of ZG006 for Injection
September 8, 2024
Announcement on Attending the 2024 Semi-annual Collective Performance Briefing for Pharmaceutical and Biological Products Companies on STAR Market
September 6, 2024
Announcement on Resolutions of the 15th Meeting of the 2nd Board of Supervisors
August 23, 2024
Announcement on Voluntary Disclosure of Notice on Registration and Clinical Verification of Recombinant Human Thyrotropin for Injection
August 12, 2024